New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR

COPENHAGEN, Denmark; April 25, 2007 - Genmab A/S (CSE: GEN) announced today that the results of a Phase II study with ofatumumab (HuMax-CD20™) in patients with rheumatoid arthritis (RA) have been accepted for oral presentation at the 2007 Annual European Congress of Rheumatology (EULAR). The oral presentation, which will include new results from the double-blind, placebo controlled Phase II study with ofatumumab, along with data from the previous interim analysis, will be described by Professor Mikkel Østergaard, Department of Rheumatology, Copenhagen University Hospital on June 16, 2007. The abstract for the presentation will be available at www.eular.org in mid-May.

Genmab A/S and GlaxoSmithKline have a worldwide agreement to co-develop and commercialize ofatumumab.


About the study

A total of 226 patients with active RA who have previously failed one or more disease-modifying anti-rheumatic drugs (DMARDs) were enrolled in the Phase II study. Patients were randomized to one of 4 treatment groups (300 mg, 700 mg or 1000 mg of ofatumumab or placebo). Patients were permitted to continue therapy with stable doses of methotrexate and low dose prednisolone. ACR and EULAR responses were assessed in the primary intention-to-treat efficacy population at 24 weeks.

Posted: April 2007

View comments

Hide
(web2)